- NetraMark (CSE:AIAI), a micro-cap AI stock focused on optimizing clinical trials, has signed a pilot agreement with a top-five pharmaceutical company to study patient populations and develop new therapies for autoimmune disorders
- The company will generate recommendations based on genetic data provided by the client
- NetraMark is an AI stock advancing patient data analysis in the pharmaceutical industry
- NetraMark stock has added 233.33 per cent year-over-year
NetraMark (CSE:AIAI), a micro-cap AI stock focused on optimizing clinical trials, has signed a pilot agreement with a top-five pharmaceutical company to study patient populations and develop new therapies for autoimmune disorders.
The company will generate recommendations based on genetic data provided by the client using its NetraAI technology, with analyses to be segmented into key research areas, including:
- Delineating how different treatments impact biological pathways, with eyes on yielding molecular insights into these treatments.
- Investigating the biological implications behind surgical history and interventions, clarifying the potential link between clinical evaluation and gene expression.
- Refining autoimmune disorder subtypes to shed light on condition-specific biological mechanisms.
Unlike most AI-powered data technology, NetraAI is equipped with focus mechanisms fit to handle small datasets, enabling it to remove poorly correlated subsets and derive insights with the potential to increase the chances of clinical trial success.
Leadership insights
“Through this collaboration, we are taking a major step towards understanding the complex molecular dynamics of autoimmune disease,” Josh Spiegel, NetraMark’s president, said in a statement. “Our NetraAI platform is uniquely positioned to uncover patterns and relationships within the data that were previously inaccessible. This partnership highlights our commitment to empowering precision medicine and providing actionable insights that can make a tangible difference in patient outcomes.”
About NetraMark
NetraMark is an AI stock advancing patient data analysis in the pharmaceutical industry.
NetraMark stock (CSE:AIAI) is up by 4.76 per cent trading at C$1.10 per share as of 9:32 am ET. The stock has added 233.33 per cent year-over-year.
Join the discussion: Find out what everybody’s saying about this micro-cap pharmaceutical AI stock on the NetraMark Holdings Inc. Bullboard and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top image, generated by AI: Adobe Stock)
